Latest Investigation News

Page 17 of 105
Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.
Ada Torres
Ada Torres
30 Apr 2026
Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.
Ada Torres
Ada Torres
30 Apr 2026
Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.
Ada Torres
Ada Torres
30 Apr 2026
Encounter Resources (ASX:ENR) has reported a major 83% increase in the Green deposit’s inferred niobium resource at its Aileron project, lifting the combined inferred mineral resource by 54%. Meanwhile, copper-gold drilling advances in the Paterson Province as the company targets Havieron-style systems.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.
Ada Torres
Ada Torres
30 Apr 2026
Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.
Victor Sage
Victor Sage
30 Apr 2026
TG Metals reports exceptional metallurgical results from heap leach testwork on Laterite gold at Van Uden, unlocking a potential low-cost, near-term cashflow opportunity from over one million tonnes of surface material.
Maxwell Dee
Maxwell Dee
30 Apr 2026
NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.
Ada Torres
Ada Torres
30 Apr 2026
Western Mines Group reported strong March quarter progress at Mulga Tank, delivering high-grade nickel sulphide results and expanding its project portfolio with new acquisitions and a magnesite supply MoU.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Celsius Resources appoints Bardin Davis as MD to lead financing efforts for the MCB Copper-Gold Project, extends Final Investment Decision timeline to late 2026, and navigates a complex ownership dispute in the Philippines while raising A$9.3 million.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Dubber Corporation reported a historic positive underlying operating cashflow run-rate in Q3 FY26, driven by a USD 3.06 million initial payment from a Tier 1 North American communications service provider and ongoing cost reductions. Recurring revenue dipped 6% quarter-on-quarter due to portfolio optimisation and foreign exchange impacts.
Sophie Babbage
Sophie Babbage
30 Apr 2026
Solara Minerals has identified compelling gold targets at Wilgeena through soil sampling and progressed drilling at Degrussa West, while maintaining a solid cash position to support ongoing exploration.
Maxwell Dee
Maxwell Dee
29 Apr 2026

Browse the archive

Full archive